Lipid-based formulations are gaining global awareness, notably with lipid nanoparticles (LNPs) being a key component in several current COVID-19 and MRNA vaccines.
Lipid-based formulations, including liposomes and LNPs, are an effective delivery system for a variety of active pharmaceutical ingredients (APIs), particularly for complex parenteral drug products including cancer, viral, and gene therapeutics.
In this podcast, we discuss how Emergent has been involved in the manufacturing of lipid-based formulations over the past two decades, along with factors to consider with partnering with a CDMO for lipid-based formulation manufacturing.
Listen to the podcast and download the Q&A transcript below.
